Investor Overview

Stock Information
Loading data...

Shares outstanding

4,060,209 (as of 8/8/2023)

Press Releases
Sep 27, 2023

-- Padagis Determined They Will Not Challenge the Phexxi Patents -- -- Evofem Has Phexxi Patent Protection Through 2033 -- SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc.,...

Sep 11, 2023

-- Investor withdraws March 2023 Notice of Default -- -- Notes are no longer convertible to shares of common stock, removing potential dilution from the previously-reserved over 240 million shares...

Aug 22, 2023

Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced it has signed a confidential non-binding letter of intent (LOI) relating to a possible merger with a publicly-traded...

Aug 14, 2023

— On track to achieve third consecutive year of revenue growth – — Second consecutive quarter of favorable net product sales to sales and marketing expense ratio — — Reduced total...

Jul 6, 2023

-- Live moderated video webcast with members of Evofem management team on Wednesday, July 12th at 4:00 p.m. ET -- SAN DIEGO, July 6, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com.  

The U.S. contraceptive market was estimated at $7.9 billion as of 2021. Every 1% market share of the 42.2 million women in our addressable market represents more than $300 million in net product sales for Evofem.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". From May 18, 2023, until June 20, 2023, it traded under the ticker symbol "EVFMD," then reverted to the ticker symbol "EVFM".

Featured Event
Thursday, September 14, 2023
08:00 am - 08:30 am PDT

All stockholders are cordially invited to attend the 2023 Annual Meeting of Stockholders. Whether you plan to attend the Annual Meeting or not, we urge you to read the proxy statement and to vote...

View All

Latest Financial Results

Q2 2023, Ended June 30, 2023

Earnings Release
10-Q Filing
XBRL